Abstract library

1055 results for "Liver metastatic PNET".
#1034 Identification of Novel and Pathological Feature of Angiostatic Microvasculature in Liver Metastatic Pancreatic Neuroendocrine Tumors and Its Clinical Implication
Introduction: Microvasculature of liver metastatic pancreatic neuroendrocrine tumors (LM-PNETs) are unknown.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: ...none of the below
Presenting Author: Xu Han
Authors: Han X, Hexige S, Lou W
#571 Safety and Efficacy of Peptide Receptor Radionuclide Therapy after Liver Transplantation in Metastatic Neuroendocrine Tumors
Introduction: Liver transplantation is an important option for patients of neuroendocrine tumors (NET) with metastases limited to the liver. Peptide receptor radionuclide therapy (PRRNT) is effective in the management of metastatic NET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Dr. Richard P Baum
#148 Near-complete regression of liver metastatic lesions in a patient with advanced pancreatic gastrinoma in response to somatostatin analogue therapy following cytoreductive surgery
Introduction: Although the majority of pancreatic NETs present with hepatic metastases, surgery with curative intent should be the first consideration. Cytoreductive surgery by resection of primary and secondary deposits may be of value in achieving local or endocrine symptoms control.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Dorota Dworakowska
Authors: Dworakowska D, Whyte M, Kane P, Patel A, ...
#893 The Role of Primary Resection and Hepatic Resection in the Management of Metastatic Pancreatic Neuroendocrine Tumors with Irresectable Liver Metastases
Introduction: More than 40% of pancreatic neuroendocrine tumor (PNET) patients have liver metastases (LM) at diagnosis. Whilst it is agreed that, where possible, curative surgery offers the best outcomes, the role of debulking surgery in the context of irresectable LM remains unclear.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Surgical treatment
Presenting Author: Mr Logan E Mills
Keywords: liver
#1604 Resection of Liver Metastases in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinomas: A Nordic Multicenter Study
Introduction: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) are generally characterized by synchronous metastases, high aggressiveness and a dismal prognosis. Currently, resection of liver metastases in patients with metastatic GEP-NEC is not recommended. However, the existing data are scarce.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Surgical treatment
Presenting Author: MD Renate Berget Galleberg
#1848 Liver Metastatic Disease (LMD) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): Incidence, Treatment and Survival in a Multicenter Study in Argentina. Preliminary Report. ARGENTUM GROUP
Introduction: The first observational Study from our Group in Argentina, showed 60% incidence of liver mets at initial diagnosis. The treatment encompasses a wide scope of surgical and non-surgical modalities.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Juan Manuel O'Connor
Keywords: Liver, NETs
#2781 Case Report: Whole Exon Sequencing of Primary Lesion and Metastatic Liver Lesion in Pancreatic Neuroendocrine Tumor
Introduction: Pancreatic neuroendocrine neoplasms(NENs) are classified into neuroendocrine tumors (NET) G1, G2, G3, and neuroendocrine carcinoma (NEC), which are different pathogenesis. The two kinds of tumors that occurs in the same lesion in one patient is very rare. We found high grade neuroendocrine neoplasms(NENG3) with a diameter of 0.1 cm in a patient with a pancreatic NETG2 (1.7 cm in diameter). The cells were significant atypia with Ki67 index of 60%, focal necrosis, while metastatic nodules in the liver (12, 0.1-1.1 cm in diameter) were all high grade NENG3.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Yanfen Shi
Authors: Shi Y, Zhong D, Li Y, Niu Y, ...
#2886 Risk Factors for Short Recurrence-Free Survivals after Resection of PanNET Liver Metastasis: Single Institutional Analysis
Introduction: Although the treatment of PanNEN has improved survivals with development of pharmacotherapy recently, surgery is the first choice if curative resection is expected to be achieved. However, most of the patients undergo recurrence after resection of the liver metastasis even after curative resection. Therefore, it is important to identify who gains longer RFS by resection.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: M.D., Ph.D. Toshihiko Masui
Authors: Masui T, Anazawa T, Nagai K, Sato A, ...
#182 Ki-67 (MIB-1) Proliferative Activity and Beta-Catenin Immunoexpression in Liver Metastases of Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Assessment of liver metastases biology features associated with cell proliferation and adhesion has a strong prognostic impact in patients with gastroenteropancreatic (GEP) neuroendocrine carcinomas.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD, PhD Vera V. Delektorskaya
#504 Metastatic Neuroendocrine Carcinoma (mNETs)
Introduction: No existing study evaluates the feasibility and efficacy of laparoscopic liver resections in patients with mNETs. This study presents our experience of a multimodal cytoreductive approach in a NET tertiary referral unit.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Michael White
Keywords: liver, surgery